{
  "abstract": "Introduction and Objectives Obstructive sleep apnoea (OSA) causes significant symptom burden to patients and is associated with cardiovascular and metabolic complications if it is untreated. Current evidence highlights the diagnostic challenge of OSA due to a lack of correlation between the severity of disease and its heterogeneous symptoms and associated comorbidities. This study determines the prevalence of sleep apnoea and its overlap syndromes, and investigates its association with hypertension, type 2 diabetes mellitus and obesity in patients who developed acute hypercapnic respiratory failure.Methods A retrospective review was performed on patients who required BiPAP therapy for acute hypercapnic respiratory failure over a 12-month period. Patients were identified via the data analysis team and data was accessed using hospital electronic records. Eligibility criteria were summarised in table 1. Primary outcome included oxygen desaturation index (ODI) as determined by overnight pulse oximetry. Secondary outcomes included diagnoses of chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), hypertension, type 2 diabetes mellitus and obesity.Results Out of 149 patients who had BiPAP therapy for acute hypercapnic respiratory failure, 53 patients were included in the study. 16 patients representing 30.19% of patients studied underwent screening with overnight pulse oximetry. 13 patients representing 81.25% of patients screened were found to have evidence of sleep apnoea with a mean ODI of 30.92 ± 21.31 events per hour of sleep. 10 patients representing 76.92% of patients diagnosed with sleep apnoea had overlap syndromes with COPD or OHS. There was no statistically significant correlation between the severity of sleep apnoea and the prevalence of hypertension, type 2 diabetes mellitus and obesity, p = 0.70.Abstract P52 Table 1Patient eligibility criteria presented in n (%)Conclusions This study highlights the importance of screening patients who develop acute hypercapnic respiratory failure for evidence of sleep apnoea using the overnight pulse oximetry test. The STOP-BANG questionnaire should be used in this patient cohort to select high risk patients for the screening test. Although polysomnography remains the gold standard diagnostic test for OSA, continuous positive airway pressure (CPAP) therapy is the mainstay of treatment for central and obstructive sleep apnoea and it has been shown to improve mortality in patients with OSA.",
  "authors": [
    {
      "affiliations": [
        "Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"
      ],
      "name": "ML Chan"
    },
    {
      "affiliations": [
        "Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"
      ],
      "name": "T Bongers"
    }
  ],
  "title": "P52 Prevalence of sleep apnoea among patients who required bilevel positive airway pressure (BiPAP) therapy for acute hypercapnic respiratory failure – a single-centre retrospective study",
  "uid": "d9be5e93-090a-5596-a79b-d2134ebda3a0"
}